Valneva’s Chikungunya Vaccine Receives Updated ACIP Recommendation Amid Safety Review

Valneva ( (VALN) ) has issued an update.

On April 16, 2025, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) updated its recommendation for Valneva’s chikungunya vaccine, IXCHIQ®, for travelers aged 18 and over to areas with chikungunya outbreaks. The ACIP also recommended a precaution for those aged 65 and over due to six reported serious adverse events. Despite these events, no causal link was established, and Valneva continues to monitor safety. The company has supplied 80,000 doses globally and recently received an order for 50,000 more doses for La Réunion amid an outbreak.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s stock score reflects a company with improving financial metrics but still facing profitability hurdles. The technical analysis indicates some positive long-term momentum, but valuation concerns persist due to negative earnings. The earnings call provides a balanced outlook with both optimistic guidance and notable challenges. These factors combined suggest moderate potential, but with significant risks.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and is involved in developing vaccine candidates for Lyme disease, Shigella, Zika virus, and other global public health threats.

YTD Price Performance: 43.86%

Average Trading Volume: 83,131

Technical Sentiment Signal: Buy

Current Market Cap: $570.6M

See more data about VALN stock on TipRanks’ Stock Analysis page.